Tue, May 20, 2:05 PM (54 days ago)
**Summary of FOXO Technologies Inc. (FOXO) Q1 2025 Financial Performance** **Overview:** FOXO Technologies Inc. (FOXO) reported its financial results for the quarter ended March 31, 2025. The company operates in two segments: Healthcare and Labs and Life. The Healthcare segment includes behavioral health services and a rural hospital, while the Labs and Life segment focuses on epigenetic biomarker technology. **Financial Highlights:** - **Revenue:** Total revenue was $3.2 million, driven by the acquisitions of Myrtle and RCHI, which contributed $0.5 million and $2.7 million, respectively. - **Operating Expenses:** Total operating expenses were $4.7 million, including direct costs of revenue, research and development, and selling, general, and administrative expenses. - **Net Loss:** The company reported a net loss of $620,808,000, primarily due to high operating expenses and interest costs. - **Cash Flow:** The company used $1.3 million in cash from operating activities, partially offset by $1.3 million from financing activities. - **Liquidity:** As of March 31, 2025, FOXO had $16.9 million in cash and cash equivalents, with a working capital deficit of $25.5 million. **Segment Performance:** - **Healthcare:** Generated $3.2 million in revenue but reported a segment loss of $844,598,000 due to high operating costs. - **Labs and Life:** Reported a segment loss of $23,005,000, with minimal revenue contribution. **Key Financial Metrics:** - **Gross Margin:** Not explicitly stated but implied to be negative due to high direct costs of revenue. - **Operating Margin:** Significantly negative, reflecting high operating expenses relative to revenue. - **Profit Margins:** The company is not profitable, with a substantial net loss. **Trends and Uncertainties:** - **Revenue Growth:** The company is focusing on expanding its healthcare operations and epigenetic technology, which may drive future revenue growth. - **Cost Management:** FOXO needs to control operating expenses to improve profitability. - **Liquidity Risks:** The company faces significant liquidity risks, requiring ongoing capital raising efforts. **Future Operations Impact:** - **Strategic Acquisitions:** FOXO plans to continue acquiring healthcare facilities and expanding its epigenetic technology offerings. - **Capital Raising:** The company will need to secure additional funding to support operations and growth initiatives. **Conclusion:** FOXO Technologies Inc. is in a challenging financial position, with significant losses and liquidity concerns. The company's strategy focuses on expanding healthcare operations and epigenetic technology, but it must address high operating costs and secure additional funding to ensure sustainability.